GLP-1 Side Effects: What the Clinical Trials Actually Report — and What to Do About Each One

Bottom line: The most common GLP-1 side effect — nausea — affects roughly 1 in 3 users early in treatment and resolves for most by week 12. Serious adverse events are rare. The clinical trial data from STEP 1 (68 weeks) and SURMOUNT-1 (72 weeks) shows a manageable safety profile for the majority of participants. Understanding what to expect and how to manage each effect significantly reduces early discontinuation.

---

What the Clinical Trials Actually Report

The side effect data for GLP-1 medications comes primarily from two large Phase 3 trials: STEP 1 (semaglutide, NEJM 2021, n=1,961) and SURMOUNT-1 (tirzepatide, NEJM 2022, n=2,539). Both ran controlled arms against placebo, which allows direct comparison between the drug’s effect and background noise.

The most frequent adverse events from SURMOUNT-1:

Side effect	Tirzepatide group	Placebo group
Nausea	30–44%	6–9%
Constipation	24%	11%
Diarrhea	16%	10%
Vomiting	9%	3%
Decreased appetite	33%	10%

The key context these tables usually omit: severity grading. In SURMOUNT-1, the vast majority of GI side effects were classified as mild to moderate. Severe GI events occurred in under 5% of the tirzepatide group. And the temporal pattern matters: side effects peaked during dose escalation (weeks 1–20) and decreased substantially thereafter.

Discontinuation due to adverse events: 6.3% of tirzepatide participants vs 2.6% placebo. That means 94% of participants tolerated the medication through the 72-week trial.

---

The Dose Escalation Design — Why Side Effects Are Front-Loaded

GLP-1 protocols don’t start at full dose. The standard titration schedule for tirzepatide:

• Weeks 1–4: 2.5mg (starter dose)
• Weeks 5–8: 5mg
• Weeks 9–12: 7.5mg
• Weeks 13–16: 10mg (maintenance for many)
• Weeks 17+: 12.5mg or 15mg (if tolerated and needed)

This slow escalation is specifically designed to let GI adaptation occur before the therapeutic dose is reached. Providers who rush patients to full dose in weeks 2–3 see higher discontinuation rates. Telehealth programs like Gala build slow escalation into the protocol precisely because the trial data shows it significantly reduces early GI burden.

If side effects are significant at a given dose, most protocols allow the dose to hold for an additional 4 weeks before escalating — or step back temporarily. This flexibility is built in.

---

Managing Each Major Side Effect

Nausea: Most common in the first 4–8 weeks. Strategies that have documented effect: eating smaller meals (large meals significantly worsen nausea), avoiding high-fat foods, eating slowly, taking the medication in the evening so peak nausea occurs during sleep. Ginger (250mg capsules, 3–4 times daily) has RCT evidence for chemotherapy-induced nausea and clinical use in GLP-1 protocols. Anti-nausea medications (ondansetron, promethazine) can be prescribed if needed.

Constipation: Affects about 24% of users, often peaking at weeks 4–8. Increase fluid intake to 2–3 liters daily; the medication reduces gastric emptying and overall gut motility. Dietary fiber increase (25–38g/day) and osmotic laxatives (polyethylene glycol) are first-line interventions. Stimulant laxatives (senna) work but can create dependency with chronic use.

Decreased appetite: This is pharmacologically intended — GLP-1 reduces hunger signals. The risk is under-eating, which accelerates lean mass loss. Most clinical protocols target 500–750 calories below maintenance, not severe restriction. Protein intake should be maintained above 80–100g/day regardless of reduced appetite.

Hair thinning (telogen effluvium): Not listed in the primary trial endpoints because it occurs indirectly — from rapid weight loss, not the medication itself. Any significant caloric deficit triggers temporary hair shedding 3–6 months after weight loss begins. It resolves without intervention as weight stabilizes. Adequate protein intake (1.2–1.6g/kg/day) is the primary mitigation.

---

The Serious Events That Are Actually Rare

Pancreatitis: SURMOUNT-1 reported pancreatitis in 0.3% of tirzepatide participants vs 0.2% placebo. The absolute difference is small. History of pancreatitis is a contraindication for GLP-1 use — telehealth platforms screen for this during intake.

Gallbladder disease: Rapid weight loss increases gallstone risk independent of the medication — the medication accelerates the underlying risk. SURMOUNT-1 reported cholecystitis in 0.6% tirzepatide vs 0.2% placebo. For people with existing gallstones or gallbladder disease, this should be discussed with a physician before starting.

Thyroid C-cell tumors: Observed in rodent studies at exposures multiples above clinical doses. Not observed in human clinical trials. The FDA requires a warning. The medication is contraindicated for people with personal or family history of medullary thyroid carcinoma or MEN 2.

Cardiovascular: GLP-1 receptor agonists have actually demonstrated cardiovascular benefit in multiple large outcome trials (LEADER for liraglutide, SUSTAIN-6 for semaglutide) — reduced MACE (major adverse cardiovascular events) vs placebo in high-risk populations. This is the opposite of a cardiovascular concern.

---

Who Should Not Use GLP-1 Medications

The clinical contraindications are specific, not general:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• History of pancreatitis
• Pregnancy (the medications are discontinued 2 months before planned pregnancy)
• Severe kidney disease (for some formulations)
• Known hypersensitivity to the active ingredient

These are screened during the physician intake assessment at any telehealth platform. Compounded GLP-1 programs require physician review of health history before prescribing — the intake questionnaire specifically screens for the above conditions.

---

The Bottom Line on Safety

The clinical trial data is clear: for people without the specific contraindications listed above, GLP-1 medications have a manageable safety profile at the doses used for weight management. The early GI side effects are real, affect roughly 1 in 3 users, and resolve for the majority within 8–12 weeks. The serious events that generate news coverage are rare and largely screened for by the intake process.

The decision to start GLP-1 therapy belongs to a physician who has reviewed your health history. What the data shows is that the benefit-risk calculation is favorable for most eligible patients — and that the side effects that cause most people concern are front-loaded, manageable, and transient.

[Compare compounded GLP-1 programs on price, dose escalation protocols, and physician oversight at GLP-1 Weight Loss Programs Compared 2026.] [For the full annual cost difference between brand-name and compounded GLP-1 — including per-pound-lost calculations — see The Honest Math on GLP-1 Alternatives in 2026.] [To understand how GLP-1 medications work at the hormonal level, see What Is Semaglutide? GLP-1 Explained.]

---

This article is informational only and does not constitute medical advice. Side effect data is sourced from published clinical trials (STEP 1, SURMOUNT-1). Compounded GLP-1 medications require physician prescription. Always discuss your health history and medications with a licensed physician before starting any weight management program. This article contains affiliate links — Verto earns a commission for qualifying consultations at no cost to you.